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Abstract: 
Dose remote preconditioning by aortic constriction (RPAC) affords cardioprotection similar to 
classical or other remote ischemic preconditioning stimulus? Moreover study was also designed 
to investigate role of inducible nitric oxide synthase in remote preconditioning by aortic 
constriction. There are sufficient evidences that “ischemic preconditioning” has surgical 
applications and afford clinically relevant cardioprotection. Transient occlusion of circumflex 
artery, renal artery, limb artery or mesenteric artery preconditions the myocardium against 
ischemia reperfusion injury in case of ischemic heart disease leading to myocardial infraction. 
Here abdominal aorta was selected to produce RPAC. Four episodes of Ischemia-reperfusion of 
5 min each to abdominal aorta produced RPAC by assessment of infract size, LDH and CK.  
These studies suggest RPAC produced acute (FWOP) and delayed (SWOP) cardioprotective 
effect. RPAC demonstrated a significant decrease in Ischemia-reperfusion induced release of 
LDH, CK and extent of myocardial infract size. L-NAME (10 mg/Kg i.v.), Aminoguanidine (150 
mg/Kg s.c.), Aminoguanidine (300 mg/Kg s.c.), S-methyl isothiourea (3 mg/Kg i.v.), 1400W (1 
mg/Kg i.v.) administered 10 min. before global ischemia reperfusion produced no marked effect. 
Aminoguanidine (150 mg/Kg s.c.), Aminoguanidine (300 mg/Kg s.c.), S-methyl isothiourea (3 
mg/Kg i.v.), 1400W (1 mg/Kg i.v.) pretreatment after RPAC produced no significant effect on 
acute RPAC induced decrease in LDH, CK and infract size, whereas L-NAME (10 mg/Kg i.v.) 
increased RPAC induced decrease in LDH, CK and infract size.  Most interesting observation is 
in delayed RPAC, where all NOS inhibitors pretreatment attenuate RPAC induced decrease in 
LDH, CK and infract size. In conclusions, “Remote preconditioning by aortic constriction” 
(RPAC) affords cardioprotection similar to classical or other remote ischemic preconditioning 
stimulus. Moreover, late or delayed phase of RPAC has been mediated by inducible nitric oxide 
synthase (iNOS) whereas it has not involved in acute RPAC. 
 
Key words: Remote preconditioning by aortic constriction (RPAC), L-NAME, Aminoguanidine, 
S-methyl isothiourea, 1400W, NOS inhibitors, Creatine phosphokinase (CK), Lactate 
dehydrogenase (LDH), Inducible Nitric Oxide Synthase (iNOS), Cardioprotection. 
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Introduction 
Myocardial Infract size is an established determinant of clinical complications and patient 
survival in an event of acute coronary occlusion. Ischemic heart disease leading to myocardial 
infarction is considered to be one of the major causes of cardiovascular morbidity and mortality. 
Revascularization of ischemic heart with thrombolytic agents, angioplasty or saphenous vein 
grafting is primary requirement.  Moreover, a delay to institute reperfusion deprives most of its 
beneficial effects as a direct function of time.  Thus attention has been focused to understand the 
adaptive mechanisms that will make the myocardium more resistant to ischemia of longer 
duration and to restore its viability on reperfusion. Repeated short episodes of ischemia-
reperfusion have been demonstrated to make the myocardium transiently more resistant to the 
deleterious effects of subsequent and prolonged ischemic insult.  This paradoxical form of 
myocardial adaptation has been termed as ischemic preconditioning which was reported to 
provide protection against infract size and arrhythmias and improving post ischemic contractile 
function. Thus ischemic preconditioning has surgical application and affords clinically relevant 
cardio protection. Preconditioning has been reported to protect the myocardium even in diseased 
states such as hypertrophy and diabetic myocardium 1-3. 
 
Ischemic preconditioning is acquired by transient ischemic stress in the same tissue or organ4.  
Short occlusions of renal artery4 or mesenteric artery5,6 or limb artery7,8,9, also precondition that 
myocardium against ischemia reperfusion injury. Ischemic stress in the remote regions termed as 
“remote preconditioning”. The cardio protective effects of ischemic preconditioning are biphasic. 
An early effect which lasts for 1-2 h and delayed effect which appears after 24 h. However, the 
delayed effect of remote preconditioning is not yet investigated 5. 
 
The antiarrythmic effect of classical ischemic preconditioning involves activation of soluble 
guanylate cyclase through NO and subsequent elevation of cGMP 10,11,12. In contrast to limited 
involvement of NO in classical ischemic preconditioning, substantial evidence implicates it in 
delayed ischemic preconditioning 13,14 . NO can act as a trigger as well as mediator of delayed 
phase of ischemic preconditioning.  Delayed cardioprotective effect ischemic preconditioning is 
accompanied by increased activity of Nuclear factor Kappa-B (NF-κβ) 15 which may in turn 
induce the expression of iNOS.  It is interesting to note that selective iNOS inhibitors such as 
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aminoguaidine and S-methyl-isothiourea, when administered before sustained ischemia abolish 
the preconditioning – induced delayed cardioprotection against stunning 8 and infraction 16,17. 
Moreover administration of endotoxin and nontoxic derivative MLA confers preconditioning like 
delayed cardioprotective through iNOS induction18,19. Role of inducible nitric oxide synthase by 
intestinal ischaemia induce late preconditioning against myocardial infarction20. 
The present study is designed to investigate the acute and delayed cardioprotective effect of 
remote aortic preconditioning.  Moreover, it is also envisaged to study the role of inducible nitric 
oxide synthase (iNOS) in cardioprotective effect of remote preconditioning by aortic 
constriction. 
Materials and methods: 
 Animals 
Wistar albino rats (100-300 g) of either sex were employed in the present study.  They are fed on 
standard laboratory chow (Kisan Feeds Ltd., New Delhi, India) and had free access to tap water 
ad libitum. All the experimental protocols were performed according to Animals Ethical 
Committee, Gyan Vihar School of Pharmacy, and Protocol No. 42. 
Remote aortic preconditioning 
Rats were anesthetized with thiopental sodium (25 mg Kg-1 i.v.). A 2 cm long incision was given 
on the abdomen.  Lower portion of abdominal aorta was isolated and the suture (numbered 5/0) 
was passed beneath it away from the origin of renal arteries.  Aorta was occluded by tying a shoe 
lace knot and knot was untied from reperfusion.  Aorta was occluded for 5 min and was 
reperfused for 5 min.  Four such episodes were used to produce preconditioning 21. In case 
animals were to be used after 24h of aortic preconditioning the abdomen was sutured in layers 
and animals were allowed to recover. 
Global ischemia and reperfusion in isolated rat heart 
Heparin (500IU, i.p.) was administered about 20 min. before sacrificing the animal.  Heart was 
rapidly excised and immediately mounted on Langendorff’s apparatus22. Aorta was retrogradely 
perfused at a constant pressure of  70 mmHg with Kreb’s Henseleit buffer (NaC1 118mM; kc1 
4.7 mM; CaCl2 2.5mM; MgSO4.7H2O 1.2mM; NaHCO3 25 mM; Kh2PO4 1.2mM; C6H12O6 
11mM) pH 7.4, maintained AT 37OC bubbled with 95% O2 and 5% CO2.  Flow rate was 
maintained between 6-9 ml/min using Hoffman’s screw.  The heart was enclosed by a double 
walled jacket, the temperature of which was maintained by circulating water heated to 37OC.  
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Global ischaemia was produced for 30 min by blocking the in-flow Kreb’s buffer.  It was 
followed by reperfusion for 120 min.  ECG (BPL CARDIAART 108T-DIGI, New Delhi, India) 
was monitored using two silver electrodes fixed at left ventricular apex and right auricle.  ECG 
was recorded immediately after stabilization, 5 min, 15 min and 30 min during ischemia and 
immediately, 5 min, 15 min, 30 min, 60 min and 120 min after reperfusion.  Coronary effluent 
was collected at same time intervals during reperfusion for LDH and CK estimation. 
Infract size measurement 
Heart was removed from Langendorff’s apparatus.  Both the auricles and the root of aorta were 
exercised, and ventricles were kept overnight at 4OC. Frozen ventricles were sliced into uniform 
sections of 2-3 mm thickness. The slices were incubated in 1% triphenyltetrazolium chloride 
(TTC) at 37OC in 0.2 M Tris buffer (pH 7.4) for 20 min.  TTC is converted to red formazone 
pigment by NADH and dehydrogenase enzyme and therefore, stained the viable cells deep red. 
The infracted cells have lost the enzyme and cofactor and thus remained unstained or dull 
yellow. The ventricular slices were placed between two glass plates. A transparent plastic grid 
with 100 squares in 1 cm2 was placed above it. Average area of each ventricular slice was 
calculated by counting the number of squares on either side. Similarly, number of squares falling 
over non-stained dull yellow area was also counted. Infracted area was expressed as a percentage 
of total ventricular area. Whole of ventricular slices were weighed.  Infracted dull yellow part 
was dissected and weighed. Infract size was expressed as a percentage of total ventricular 
weight. 
Estimation of Lactate dehydrogenase (LDH) 
LDH was estimated in coronary effluent by 2,4-DNPH method23. 
Principle 
LDH catalyses the following reaction: 
Lactate  + NAD  Pyruvate + NADH 
The pyruvate so formed is coupled with 2,4-dinitrophenylhydrazine (2,4-DNPH) to give 
corresponding hydrazone which gives brown colour in alkaline medium.  The intensity of this 
colour is proportional to the amount of LDH activity and is measured spetrophotometrically at 
440 nm.[Figure 1] 
Estimation of Creatine phosphokinase (CPK) 
CPK was measured in the coronary effluent by modified method of Hughes24.  
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Principle 
CPK catalyses the following reaction: 
Creatine phosphate  + ADP  Creatine + ATP 
At pH 7.4, CPK catalyses  the forward reaction.  The creatine so formed, reacts with diacetyl and 
–naphthol in alkaline medium to give pink colour.  The intensity of this colour is proportional to 
enzyme activity and is measured spectrophotometrically at 520 nm. Mg2+ and cysteine are added 
as activators.  P-Chloromercuribenzoate stops the reaction by inactivating the enzyme. 
Experimental Protocol 
Twenty four groups of Wistar albino rats were employed in the present study. 
Remote Aortic Preconditioning Induced Acute or First Window of Protection (FWOP): First 
window of protection (FWOP) was observed immediately after remote aortic preconditioning. 
Group 1 (FWOP Control Group; n=6) 
Rats were subjected to surgical procedure for aortic isolation but aorta was not occluded.  Hearts 
were excised 40 min after sham operation.  Isolated hearts were perfused on Langendorff’s 
apparatus and were subjected to global ischaemia for 30 min followed by reperfusion for 120 
min. 
Group II (FWOP Remote Preconditioning by Aortic Constriction Group; n = 6) 
Rats were subjected to remote preconditioning by aortic constriction as described earlier. Hearts 
were excised immediately after last episode of reperfusion, perfused on Langendorff’s apparatus 
and were subjected to global ischaemia for 30 min followed by reperfusion for 120 min. 
Group III (FWOP L-NAME (10mg/kg i.v.) 25 Treated Control Group; n=6) 
Rats were administered 10 mg/kg of L-NAME i.v., 10 min before excising the heart for 
Langendorff’s perfusion. Rest of the protocol was same as described in group I. 
Group IV (FWOP L-NAME (10mg/kg i.v.) Treated Remote Preconditioning by Aortic 
Constriction Group; n=6) 
L-NAME (10 mg/kg i.v.) was administered during last episode of reperfusion during remote 
preconditioning by aortic constriction i.e. 10 min before isolating the heart for Langendorff’s 
perfusion.  Rest of the protocol was same as described in group I. 
Group V (FWOP Aminoguanidine (150mg/kg i.v.) 26,27 Treated Control Group; n=6) 
Rats were administered 150 mg/kg of aminoguanidine i.v. 10 min before excising the heart for 
Langendorff’s perfusion. Rest of the protocol was same as described in group I. 
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Group VI (FWOP Aminoguanidine (150mg/kg i.v.) Treated Remote Preconditioning by 
Aortic Constriction Group; n=6) 
Aminoguanidine (150 mg/kg i.v.) was administered during last episode of reperfusion during 
remote preconditioning by aortic constriction i.e. 10 min before isolating the heart for 
Langendorff’s perfusion.  Rest of the protocol was same as described in group I. 
Group VII (FWOP Aminoguanidine (300mg/kg s.c.) 28 Treated Control Group; n=6) 
Rats were administered 300 mg/kg of aminoguanidine i.v. 10 min before excising the heart for 
Langendorff’s perfusion. Rest of the protocol was same as described in group I. 
Group VIII (FWOP Aminoguanidine (300mg/kg i.v.) Treated Remote Preconditioning by 
Aortic Constriction Group; n=6) 
Aminoguanidine (300 mg/kg i.v.) was administered during last episode of reperfusion during 
remote preconditioning by aortic constriction i.e. 10 min before isolating the heart for 
Langendorff’s perfusion.  Rest of the protocol was same as described in group I. 
Group IX (FWOP S-methyl isothiourea (3mg/kg i.v.) 28 Treated Control Group; n=6) 
Rats were administered S-methyl isothiourea (3mg/kg i.v.) 10 min before excising the heart for 
Langendorff’s perfusion. Rest of the protocol was same as described in group I. 
Group X (FWOP S-methyl isothiourea (3mg/kg i.v.) Treated Remote Preconditioning by 
Aortic Constriction Group; n=6) 
S-methyl isothiourea (3mg/kg i.v.) was administered during last episode of reperfusion during 
remote preconditioning by aortic constriction i.e. 10 min before isolating the heart for 
Langendorff’s perfusion.  Rest of the protocol was same as described in group I. 
Group XI (FWOP 1400W (1mg/kg i.v) 25 Treated Control Group; n=6) 
Rats were administered 1400W (1 mg/kg i.v.) 10 min before excising the heart for Langendorff’s 
perfusion. Rest of the protocol was same as described in group I. 
Group XII (FWOP 1400W (1mg/kg i.v.) Treated Remote Preconditioning by Aortic 
Constriction Group; n=6) 
1400W (1 mg/kg i.v.) was administered during last episode of reperfusion during remote 
preconditioning by aortic constriction i.e. 10 min before isolating the heart for Langendorff’s 
perfusion.  Rest of the protocol was same as described in group I. 
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Remote Aortic Preconditioning Induced Delayed or Second Window of Protection (SWOP): 
Second window of protection (SWOP) was observed 24h after remote aortic preconditioning. 
Group XIII (SWOP Control Group; n=6) 
Rats were subjected to surgical procedure for aortic isolation but aorta was not occluded.  Hearts 
were excised 24h after sham operation.  Rest of the protocol was same as in group I. 
Group XIV (SWOP Remote Preconditioning by Aortic Constriction Group; n=6) 
Rats were subjected to remote preconditioning by aortic constriction and hearts were excised 24h 
after remote aortic preconditioning.  Rest of the protocol was same in group I. 
Group XV (SWOP L-NAME (10 mg/kg i.v.) Treated Control Group; n=6) 
Rats were subjected to same protocol as described in group XIV except that L-NAME (10 mg/kg 
i.v.) was administered 10 min before excising the heart for Langendorff’s perfusion. 
Group XVI (SWOP L-NAME (10 mg/kg i.v.)  Treated Remote Preconditioning by Aortic 
Constriction Group; n=6) 
Rats were subjected to same protocol as described in-group XIV except that L-NAME (10 mg/kg 
i.v.) was administered 10 min before excising the heart for Langendorff’s perfusion. 
Group XVII (SWOP Aminoguanidine (150 mg/kg i.v.) Treated Control Group; n=6) 
Rats were subjected to same protocol as described in group XI except that aminoguanidine 
chloride (150 mg/kg i.v.) was administered 10 min before excising the heart for Langendorff’s 
perfusion. 
Group XVIII (SWOP Aminoguanidine(150 mg/kg i.v.)  Treated Remote Preconditioning 
by Aortic Constriction Group; n=6) 
Rats were subjected to same protocol as described in-group XIV except that aminoguanidine 
(150 mg/kg i.v.) was administered 10 min before excising the heart for Langendorff’s perfusion. 
Group XIX (SWOP Aminoguanidine (300 mg/kg i.v.) Treated Control Group; n=6) 
Rats were subjected to same protocol as described in group XIII except that aminoguanidine 
chloride (300 mg/kg i.v.) was administered 10 min before excising the heart for Langendorff’s 
perfusion. 
Group XX (SWOP Aminoguanidine (300 mg/kg i.v.)  Treated Remote Preconditioning by 
Aortic Constriction Group; n=6) 
Rats were subjected to same protocol as described in-group XIV except that aminoguanidine 
(300 mg/kg i.v.) was administered 10 min before excising the heart for Langendorff’s perfusion. 
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Group XXI (SWOP S-methyl isothiourea (3mg/kg i.v.) Treated Control Group; n=6) 
Rats were subjected to same protocol as described in group XIII except that S-methyl isothiourea 
(3mg/kg i.v.) was administered 10 min before excising the heart for Langendorff’s perfusion. 
Group XXII (SWOP S-methyl isothiourea (3mg/kg i.v.) Treated Remote Preconditioning 
by Aortic Constriction Group; n=6) 
Rats were subjected to same protocol as described in-group XIV except that S-methyl 
isothiourea (3mg/kg i.v.) was administered 10 min before excising the heart for Langendorff’s 
perfusion. 
Group XXIII (SWOP 1400W (1mg/kg i.v.) Treated Control Group; n=6) 
Rats were subjected to same protocol as described in group XIII except that 1400W (1mg/kg i.v.) 
was administered 10 min before excising the heart for Langendorff’s perfusion. 
Group XXIV (SWOP 1400W (1mg/kg i.v.) Treated Remote Preconditioning by Aortic 
Constriction Group; n=6) 
Rats were subjected to same protocol as described in-group XIV except that 1400W (1mg/kg 
i.v.) was administered 10 min before excising the heart for Langendorff’s perfusion. 
 
Drugs and chemicals 
Aminoguanidine hydrogen carbonate (Lancaster Chemicals, Madras, India), 1400W ([N-(3-
(aminomethyl)benzyl)acetamidine]sulfate) (a specific iNOS inhibitor) was from Acros Organics 
(Noisy le Grand, France), dissolved in distilled water immediately before use, S-methylthiourea 
sulfate (Sigma-Aldrich USA) L-NAME (nitro-L-arginine-methylester) (non-specific iNOS 
inhibitor) (Sigma-Aldrich USA), Tris buffer was prepared by adding 50 ml of 0.2 M Tris (CDH 
chemicals, N.Delhi, India) in 32.5 ml of 0.2 M HCl and volume was made up to 200 ml with 
distilled water.  All other reagents used in the study were analar grade of Qualigens (Glaxo, 
Mumbai, India) 
Statistical analysis 
Values for enzymatic data and infract-size were expressed as mean ± S.E.M. Statistical 
significance was calculated using one way analysis of variance.  Dunnett’s test and student t test 
were employed as post-hoc tests for comparison with control group and for multiple comparisons 
between groups respectively.  A value of p < 0.05 is considered to be statistically significant. 
Sigma10 software was used for statistical analysis. 
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Results 
Effect of remote aortic preconditioning and NOS (Nitric Oxide Synthase) Inhibitors 
pretreatment on coronary flow rate and heart rate 
Global ischaemia for 30 min produced a marked decrease in coronary flow rate [Table 1] and 
heart rate [Table 2] and this decrease persisted for the entire 120 min of reperfusion.  NOS 
(Nitric Oxide Synthase) Inhibitors [L-NAME(10 mg/Kg i.v.), Aminoguanidine(150 mg/Kg s.c.), 
Aminoguanidine (300 mg/Kg s.c.), S-methyl isothiourea (3 mg/Kg i.v.), 1400W (1 mg/Kg i.v.)] 
pretreatment and remote aortic preconditioning produced no significant change in flow rate 
[Table 1] and heart rate [Table 2]. 
Effect of NOS (Nitric Oxide Synthase) Inhibitors pretreatment on ischemia/reperfusion-
induced myocardial injury 
The peak increase in release of LDH in coronary effluent of isolated rat heart subjected to global 
ischaemia and reperfusion was noted immediately and 30 min after reperfusion [Table 3], 
whereas peak increase in release of CK was noted after 5min of reperfusion. L-NAME (10 
mg/Kg i.v.), Aminoguanidine (150 mg/Kg s.c.), Aminoguanidine (300 mg/Kg s.c.), S-methyl 
isothiourea (3 mg/Kg i.v.), 1400W (1 mg/Kg i.v.) administered 10 min before removing the heart 
for ischaemia/reperfusion study using Langendorff’s apparatus produced no marked effect on 
ischaemia/reperfusion-induced in release of LDH [Table 3] CK [Table 5] and myocardial infract 
size [Table 7].  
Acute (FWOP) and Delayed (SWOP) effects of remote preconditioning by aortic 
constriction (RPAC) on ischemia/reperfusion-induced myocardial injury 
Rat heart isolated immediately (acute/FWOP) or 24 h (delayed/SWOP) after remote 
preconditioning by aortic constriction (RPAC) demonstrated a significant decrease in 
ischaemia/reperfusion induced release of LDH [Table 3,4] CK [Table 5,6] and extent of 
myocardial infract size [Table 7,8].  Remote preconditioning by aortic constriction (RPAC)  
produced acute (FWOP) and delayed (SWOP) cardioprotective effect. 
Effect of NOS (Nitric Oxide Synthase) Inhibitors on Acute (FWOP) and Delayed (SWOP) 
remote preconditioning by aortic constriction (RPAC) in ischemia/reperfusion-induced 
myocardial injury  
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In rat heart isolated immediately after remote preconditioning by aortic constriction 
(Acute/FWOP) and pretreatment with Aminoguanidine(150 mg/Kg s.c.), Aminoguanidine (300 
mg/Kg s.c.), S-methyl isothiourea (3 mg/Kg i.v.), 1400W (1 mg/Kg i.v.) produced no significant 
effect on preconditioning induced decrease in LDH [Table 3], CK [Table 5] release and 
myocardial infract size [Table 7]. L-NAME (10 mg/Kg i.v.) administration increase release of 
LDH [Table 3] CK [Table 3] in coronary effluent  and also increased myocardial infract size 
[Table 5] in Acute/FWOP remote preconditioning by aortic constriction.     
 
On the other hand, administration of L-NAME(10 mg/Kg i.v.), Aminoguanidine(150 mg/Kg 
s.c.), Aminoguanidine (300 mg/Kg s.c.), S-methyl isothiourea (3 mg/Kg i.v.), 1400W (1 mg/Kg 
i.v.) 24 hr after subjecting rat heart to remote aortic preconditioning (delayed/SWOP), attenuated 
remote preconditioning by aortic constriction (RPAC) induced decrease in LDH [Table 4], CK 
[Table 6] release in coronary effluent and myocardial infract size [Table 8]. 
Discussion 
In the present study, four episodes of occlusion of aorta followed by reperfusion markedly 
protected the rat heart against sustained ischemia and reperfusion induced myocardial injury. The 
observed acute and delayed cardio protective effect of remote preconditioning by aortic 
constriction has been supported by our earlier observation noted with remote renal 
preconditioning 4,5,6. It has been clarified that the has no limitation of this experimental 
condition, as ex vivo experimental results could be directly extrapolated into clinical setting as 
well as in vivo animal condition supported by findings by D.J. Hausenloy et al., 2007; D.J. 
Hausenloy et al., 2010 and H.E. Bøtker et al., 2010 7,8,9. In the present study the delayed cardio 
protective effect of remote by aortic constriction is attenuated with aminoguanidine, L-NAME, 
S-methyl isothiourea and 1400W (NOS inhibitors). Aminoguanidine is reported to attenuate 
endotoxin-induced delayed cardio protection 19.  
1400W, a selective iNOS inhibitor, was used to determine whether this isozyme was involved in 
the cardio-protective mechanism. 1400W was chosen because, because of its higher selectivity 
for iNOS (5000 times more selective for iNOS than for eNOS) 25. A specific role of iNOS-
derived NO as a mediator of delayed cardioprotection has also been reported for ischaemic 
preconditioning (IP). Thus, iNOS induction shown to be necessary for the development of 
delayed protection conferred by IP in anaesthetised rabbit models of myocardial infarction and 
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stunning25. Vegh et al. have also demonstrated that iNOS inhibition prevents the development of 
delayed preconditioning against arrhythmias, in the dog. Using iNOS knockout mice, Guo et al. 
have shown that targeted disruption of the iNOS gene completely abrogates the infarct-sparing 
effect of late IP, demonstrating that the activity of iNOS is indispensable for this cardioprotective 
phenomenon to occur 25. Further more, iNOS appears to be a final mediator of several other 
forms of delayed myocardial preconditioning, such as that induced by NO donors, endotoxin 
derivatives and exercise. Although recent studies suggest that adenosine A1 receptor agonist-
induced cardioprotection occurs independently of either early generation of NO or induction of 
iNOS, an implication of iNOS has also been shown in this form of pharmacological 
preconditioning25. 
 
Recent evidence has shown that the cardioprotection afforded by the late phase of ischemic 
preconditioning (PC) is mediated by upregulation of inducible nitric oxide synthase (iNOS). 
However, the specific cardiac cell type(s) that express(es) iNOS in response to ischemic PC 
remains unknown. Thus, mice underwent a sequence of six cycles of 4-min coronary 
occlusion/4-min reperfusion, which induces late PC, and tissue samples were collected at serial 
times for measurement of mRNA (Northern) and protein levels (Western). In addition, whole 
heart samples were cryosectioned for in situ hybridization and immunohistochemistry. The 
steady-state levels of iNOS mRNA in the ischemic regions started to increase at 1 h after 
ischemic PC, peaked at 3 h (201±31% of sham, n=5 P<0.01) and remained elevated at 24 h 
(177±22% of sham, n=5 P<0.01). In accordance with these data, iNOS protein expression was 
increased at 24 h (219±41% of sham, n=5 P<0.01). In contrast, neither endothelial nitric oxide 
synthase (eNOS) mRNA levels nor its protein expression changed at any time-point26. 
 
Administration of aminoguanidine (300 mg/ kg, s.c.) or S-methylisothiourea sulfate (3 mg/ kg, 
i.v.), both relative inducible NO synthase inhibitors, 60 or 30 min before sustained myocardial 
ischemia not only abolished the late preconditioning afforded by intestinal ischemia, but also 
inhibited the ability of intestinal ischemia preconditioning to significantly reduce neutrophil 
infiltration. A change in inducible NO synthase activity was not observed in normal myocardium 
24 h after intestinal ischemia, but 30 min of coronary occlusion significantly increased the 
inducible NO synthase activity in the preconditioned group, which was abolished by 
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aminoguanidine or S-methylisothiourea sulfate. In conclusion, above data provide 
pharmacological evidence that induction of inducible nitric oxide synthase, following intestinal 
ischemia, is associated with increased myocardial tolerance to infarction 24 h later 20. The same 
is confirmed in the present study that aminoguanidine (300 mg/ kg, s.c.) or S-methylisothiourea 
sulfate (3 mg/ kg, i.v.), both relative inducible NO synthase inhibitors, abolished the late 
preconditioning afforded by remote preconditioning by aortic constriction. 
 
Aminoguanidine in the dose employed is reported to inhibit selectively iNOS 27,28. The late phase 
of ischemic preconditioning is a delayed adaptive response that renders the heart relatively 
resistant to sustained ischemia and reperfusion. NO is identified as a initial signal for triggering 
the late cardio protective effect of classical ischemic preconditioning 15,16,29. Activation of pro-
inflammatory mediators such as cytokines and inducible nitric oxide synthase (iNOS) have been 
shown to contribute to myocardial injury after ischemia and reperfusion 30-32. Up regulation of 
iNOS may account to precondition the heart by brief ischemic stress. Different induction of 
mRNA for inducible nitric oxide synthase in rat smooth muscle cells in culture and in aortic 
strips has been found. One of the transcription factors that could activate gene expression in 
response to ischemic preconditioning is the nuclear factor κβ (NF-κβ).  This oxidant sensitive 
transcription factor plays a critical role in the immediate – early activation of multitude of genes 
encoding signaling and defense proteins expressed in the response to various stressful situations 
and therefore appears to be a general mediator of cellular responses to stress33-35. It is well 
established that the 5’ flanking region of iNOS gene contains a consenus sequence that NF-κβ 
and that the activation of NF- κβ is a central mechanism controlling the induction of iNOS in 
several cell types including cardiac myocytes 31,36-38. Therefore, it may be possible that the noted 
delayed cardio protective effect remote preconditioning by aortic constriction may be due to 
upregulation of iNOS due to shear stress exerted on myocardium by aortic occlusions.  This 
contention is supported by the results of the present study because aminoguanidine, a selective 
iNOS inhibitor, attenuated the delayed cardio protective effect of remote aortic 
preconditioning27,28. Our results are supported by observations, which implicate the role of iNOS 
in delayed cardio protective effect of classical ischemic preconditioning 15,16,19. It is further 
supported that pacing induced delayed protection against arrythmias is attenuated by 
aminoguanidine, an inhibitor of nitric oxide synthase39. Delayed or Second window 
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preconditioning induced by adenosine A1 receptor activation is independent of early generation 
of nitric oxide or late induction of inducible nitric oxide synthase 40. 
 
Induction of iNOS requires a lag phase. Acute cardio protective effect of remote preconditioning 
by aortic constriction was observed immediately after the preconditioning stimulus.  Therefore 
the involvement of iNOS in it, may be remote because induction of iNOS require some lag time 
26,27.  Moreover, this contention is further supported by our results which have demonstrated that 
aminoguanidine, S-methyl isothiourea, 1400W in the dosage employed has produced no notable 
effect on acute cardio-protective effect of remote preconditioning afforded by aortic constriction. 
Therefore, it may be possible that the acute cardio-protective effect of remote preconditioning by 
aortic constriction may be mediated through the activation of eNOS may be as result of shear 
stress 32,41 and confirmed by present study because L-NAME, a non-specific NOS inhibitor 
abolished acute cardioprotective effect produced by remote preconditioning by aortic 
constriction.  
 
Over the past decade, an enormous number of studies (>100) have focused on the role of nitric 
oxide (NO) in myocardial ischemia. It is important to distinguish the function of NO in 
unstressed (non-preconditioned) myocardium from its function in preconditioned myocardium 
(i.e. myocardium that has shifted to a defensive phenotype in response to stress). The time has 
come to translate this enormous body of experimental evidence into clinically useful therapies by 
harnessing the cytoprotective properties of NO 42-46. 
Preconditioning is in experimental studies the most powerful mode of cardio protection known. 
The signal transduction pathways involve a variety of trigger substances, mediators, receptors, 
and effectors. The studies of preconditioning in cardiac surgery provide conflicting results but 
the majority of studies show that ischemic preconditioning is an effective adjunct to myocardial 
protection. However, ischemic preconditioning with repeated clamping of the aorta will never 
get widespread use. If the “preconditioning response” is to be exploited in cardiac surgery, 
targeting the underlying molecular mechanisms must provide easily applicable techniques or 
drugs, which are shown in large scale clinical studies to be beneficial 47. Remote ischemic 
preconditioning increases the tolerance of the myocardium to ischemia, reduces ischemic chest 
15 
 
discomfort during coronary balloon occlusion, and reduces the prevalence of cardiac troponin I 
[cTnI] release after elective PCI 48. The data add to the growing number of studies suggesting 
that remote ischemic preconditioning is a safe, effective, noninvasive, and cost-effective strategy 
for reducing ischemic cardiac damage in settings where myocardial ischemic damage is expected 
49. 
Conclusions 
On the basis of the above results and discussion, it can be concluded that remote preconditioning 
by aortic constriction has produced acute and delayed cardioprotective effect as found earlier 
with classical and other remote preconditioning stimulus.  Recent evidence has shown that the 
cardioprotection afforded by the late phase of ischemic preconditioning (PC) is mediated by 
inducible nitric oxide synthase (iNOS). The steady-state levels of iNOS mRNA in the ischemic 
regions started to increase at 1 h after ischemic PC, peaked at 3 h and remained elevated at 24 h. 
In accordance with these data, iNOS protein expression was increased at 24 h 26. In the present 
study iNOS has been involved in the delayed cardio-protective effect afforded by remote 
preconditioning by aortic constriction as supported by above findings.  On the other hand 
activation of iNOS may not participate in acute cardio-protective effect of remote 
preconditioning by aortic constriction.   
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Table 1: Acute Effect (FWOP) and delayed effect (SWOP) of remote preconditioning by aortic  constriction (RPAC) and and NOS inhibitors  Pretreatment on Coronary Flow Rate (ml/min) 
in Isolated Rat Heart Subjected to Global Ischaemia (30 min) and Reperfusion (120 min). 
Groups BASAL Imm.R. 5 min R. 15 min.R. 30 min.R. 60 min.R. 120 min.R. 
(I) Sham (FWOP) 8.40±0.13 4.40*±0.24 5.32*±0.05 4.98*±0.18 4.16*±0.42 2.90*±0.48 1.24*±0.5 
(II) RAPC (FWOP) 8.22±0.30 4.36*±0.37 4.94*±0.29 4.30*±0.50 4.92*±0.67 2.58*±0.56 1.96*±0.41 
(III) L-NAME (10 mg/Kg i.v) pretreatment immediately after Sham operation (FWOP) 10.38±1.53 7.04*±0.72 4.92*±0.72 4.04*±0.71 3.92*±0.73 2.85*±0.40 2.49*±0.51 
(IV) L-NAME (10 mg/Kg i.v) pretreatment immediately after RPAC (FWOP) 9.73±0.49 5.98*±0.49 4.82*±1.06 3.93*±1.12 3.53*±0.20 3.19*±0.61 2.63*±0.24 
(V) Aminoguanidine (150 mg/Kg s.c) pretreatment immediately after Sham operation (FWOP) 8.06±0.63 4.78*±0.79 3.98*±0.75 3.70*±0.70 2.58*±0.65 2.02*±0.47 1.66*±0.42 
(VI) Aminoguanidine (150 mg/Kg s.c) pretreatment immediately after RPAC (FWOP) 9.66±0.96 6.86*±1.19 6.46*±1.06 6.00*±0.71 5.20*±1.10 4.30*±0.74 3.46*±0.46 
(VII) Aminoguanidine (300 mg/Kg s.c) pretreatment immediately after Sham operation (FWOP) 9.51±0.35 5.79*±0.62 5.96*±0.41 5.06*±1.25 4.17*±0.83 4.06*±0.62 3.24*±0.82 
(VIII) Aminoguanidine (300 mg/Kg s.c) pretreatment immediately after RPAC (FWOP) 11.23±0.59 5.29*±0.45 4.02*±0.37 3.95*±0.48 2.79*±0.63 2.86*±0.94 2.71*±0.93 
(IX) S-methyl isothiourea (3 mg/Kg i.v)  pretreatment immediately after Sham operation (FWOP) 9.67±0.28 6.19*±1.02 5.39*±1.02 5.26*±0.63 3.82*±0.63 3.72*±0.49 3.43*±0.59 
(X) S-methyl isothiourea (3 mg/Kg i.v)pretreatment immediately after RPAC (FWOP) 9.52±0.69 7.03*±0.54 6.08*±0.97 5.49*±0.37 4.94*±0.47 4.62*±0.92 3.49*±0.80 
(XI) 1400W (1 mg/Kg i.v)  pretreatment immediately after Sham operation (FWOP) 11.03±0.63 7.84*±0.81 3.83*±0.49 3.94*±1.05 2.68*±0.64 2.40*±0.67 1.97*±0.62 
(XII) 1400W (1 mg/Kg i.v)pretreatment immediately after RPAC (FWOP) 9.97±0.96 5.86*±1.30 4.60*±0.28 3.98*±0.52 2.80*±0.27 2.73*±0.31 1.29*±0.53 
(XIII) Sham (SWOP)   8.20±0.12 4.84*±1.22 5.26*±0.95 4.04*±1.34 2.06*±0.52 2.62*±0.28 1.02*±0.17 
(XIV) RAPC (SWOP) 8.18±0.20 4.76*±0.93 5.20*±0.78 4.40*±1.09 4.06*±1.25 2.46*±1.04 1.30*±0.30 
(XV) L-NAME (10 mg/Kg i.v) pretreatment immediately after Sham operation (SWOP) 10.46±0.64 6.04*±0.58 7.32*±0.30 4.78*±1.21 3.86*±0.94 3.04*±1.02 3.02*±0.41 
(XVI) L-NAME (10 mg/Kg i.v) pretreatment 24 hr. after RAPC 11.92±0.28 5.49*±0.82 5.60*±0.25 3.93*±0.72 3.86*±0.63 2.97*±0.79 2.08*±0.53 
(XVII) Aminoguanidine (150 mg/Kg s.c) pretreatment immediately after Sham operation (SWOP) 9.42±0.25 5.12*±0.49 4.82*±0.46 3.92*±0.52 2.80*±0.40 2.08*±0.44 1.28*±0.10 
(XVIII) Aminoguanidine (150 mg/Kg s.c) pretreatment 24 hr. after RAPC 10.96±0.60 7.26*±0.92 7.68*±1.27 6.48*±1.18 4.20*±1.00 3.98*±0.89 2.18*±0.61 
(XIX) Aminoguanidine (300 mg/Kg s.c) pretreatment immediately after Sham operation (SWOP) 10.80±1.27 7.90*±1.03 7.79*±0.22 5.42*±0.23 4.54*±0.74 3.64*±0.62 3.50*±0.83 
(XX) Aminoguanidine (300 mg/Kg s.c) pretreatment immediately after RPAC (SWOP) 11.82±0.44 5.92*±0.39 5.62*±1.20 5.39*±0.85 3.03*±0.59 2.91*±0.29 2.84*±0.67 
(XXI) S-methyl isothiourea (3 mg/Kg i.v) pretreatment immediately after Sham operation (SWOP) 9.07±0.73 4.97*±0.85 4.69*±0.82 4.49*±0.46 4.06*±0.52 3.05*±0.85 2.94*±1.03 
(XXII) S-methyl isothiourea (3 mg/Kg i.v)pretreatment immediately after RPAC (SWOP) 10.57±0.59 5.70*±0.31 5.62*±0.73 5.20*±0.72 3.98*±0.83 2.74*±0.94 2.79*±0.47 
(XXIII) 1400W (1 mg/Kg i.v)  pretreatment immediately after Sham operation (SWOP) 9.73±1.34 6.39*±0.76 6.17*±0.68 4.92*±0.64 2.99*±0.95 2.82*±0.42 1.74*±0.29 
(XXIV) 1400W (1 mg/Kg i.v)pretreatment immediately after RPAC (SWOP) 8.94±1.42 5.89*±1.07 5.18*±0.87 4.05*±0.77 3.97*±1.18 3.32*±0.79 2.59*±1.02 
 
Vales are mean ±  SEM (n=6).  Coronary flow rate was measured after stabilization (basal), immediately (Imm.R), 5 (5min.R), 15 (15 min.R), 30 (30 min. R.), 60 (60 min. R.) and 120 (120 min. R.) min 
after reperfusion (R).  *P<0.05 vs Basal, Sham denotes sham operated. 
 
 
 
 
 
Table 2: Acute Effect (FWOP) and delayed effect (SWOP) of remote preconditioning by aortic  constriction (RPAC) and NOS inhibitors  Pretreatment on Heart Rate (beats/min) in isolated 
Rat Heart Subjected to Global Ischaemia (30 min) and Reperfusion (120 min). 
Groups BASAL 5 min R. 15 min.R. 30 min.R. 60 min.R. 120 min.R. 
(I) Sham (FWOP) 205±30 144*±20 174*±20 146*±15 132*±10 126*±15 
(II) RAPC (FWOP) 228±35 120*±30 180*±30 144*±30 156*±30 114*±19 
(III) L-NAME (10 mg/Kg i.v) pretreatment immediately after Sham operation (FWOP) 226±18 146*±31 164*±08 152*±13 143*±22 111*±25 
(IV) L-NAME (10 mg/Kg i.v) pretreatment immediately after RPAC (FWOP) 207±22 122*±13 178*±26 143*±28 140*±07 119*±32 
(V) Aminoguanidine (150 mg/Kg) pretreatment immediately after Sham operation (FWOP) 182±12 124*±23 142*±15 136*±15 138*±20 124*±20 
(VI) Aminoguanidine (150 mg/Kg) pretreatment immediately after RAPC (FWOP) 216±26 120*±19 114*±17 132*±08 120*±10 112*±10 
(VII) Aminoguanidine (300 mg/Kg) pretreatment immediately after Sham operation (FWOP) 178±23 136*±22 159*±18 153*±26 134*±06 125*±13 
(VIII) Aminoguanidine (300 mg/Kg) pretreatment immediately after RAPC (FWOP) 207±24 148*±24 136*±25 132*±14 122*±16 118*±19 
(IX) S-methyl isothiourea (3 mg/Kg i.v) pretreatment immediately after Sham operation (FWOP) 182±19 147*±26 177*±28 141*±28 132*±24 131*±20 
(X) S-methyl isothiourea (3 mg/Kg i.v.)pretreatment immediately after Sham operation (FWOP) 221±33 149*±31 168*±32 168*±21 152*±27 141*±28 
(XI) 1400W (1 mg/Kg i.v)  pretreatment immediately after Sham operation (FWOP) 233±21 130*±19 188*±25 171*±23 139*±22 102*±24 
(XII) 1400W (1 mg/Kg i.v)pretreatment immediately after RPAC (FWOP) 194±16 127*±12 152*±34 166*±11 127*±30 126*±18 
(XIII) Sham (SWOP) 228±30 120*±20 138*±10 139*±20 126*±14 113*±12 
(XIV) RAPC (SWOP) 252±30 126*±15 180*±20 120*±08 114*±15 125*±10 
(XV) L-NAME (10 mg/Kg i.v) pretreatment immediately after Sham operation (SWOP) 203±16 147*±31 179*±18 152*±13 133*±24 108*±16 
(XVI) L-NAME (10 mg/Kg i.v) pretreatment immediately after RPAC (SWOP) 225±18 132*±24 158*±30 138*±20 143*±19 122*±21 
(XVII) Aminoguanidine (150 mg/Kg s.c.) pretreatment 24 hr. after Sham operation 218±09 140*±12 146*±11 134*±05 123*±08 96*±13 
(XVIII) Aminoguanidine (150 mg/Kg s.c.) pretreatment 24 hr. after RAPC 234±11 122*±16 152*±16 140*±11 144*±15 118*±07 
(XIX) Aminoguanidine (300 mg/Kg s.c.) pretreatment immediately after Sham operation (SWOP) 223±15 146*±17 183*±27 159*±16 149*±07 123*±19 
(XX) Aminoguanidine (300 mg/Kg s.c.) pretreatment immediately after RAPC (SWOP) 193±23 135*±21 177*±15 148*±19 113*±12 116*±07 
(XXI) S-methyl isothiourea (3 mg/Kg i.v)  pretreatment immediately after Sham operation (SWOP) 202±08 149*±29 169*±14 161*±27 151*±23 121*±14 
(XXII) S-methyl isothiourea (3 mg/Kg i.v)pretreatment immediately after Sham operation (SWOP) 189±26 138*±06 168*±22  182*±06 147*±15 128*±10 
(XXIII) 1400W (1 mg/Kg i.v)  pretreatment immediately after Sham operation (SWOP) 253±07 128*±31 176*±25 173*±15 128*±19 108*±12 
(XXIV) 1400W (1 mg/Kg i.v)pretreatment immediately after RPAC (SWOP) 199±28 142*±22 149*±17 141*±27 132*±06 126*±22 
Vales are mean ±  SEM (N=5).  Heart rate was measured after stabilization (basal), 5 (5 min.R.), 15 (15 min. R.), 30 (30 min.R.), 60 (60 min. R.) and 120 (120 min. R.) min after reperfucion (R ). 
*P<0.05 vs Basal, Sham denotes sham operated. 
Table - 3: Acute Effect (FWOP) of  Remote Preconditioning  by Aortic Constriction and NOS inhibitors  Pretreatment  on Lactate Dehydrogenase (LDH) Release in coronary Effluent of  
Isolated Rat Heart Subjected to Global Ischaemia (30 min) followed by Reperfusion (120 min). 
L-NAME (10 mg/Kg i.v) pretreatment (FWOP) Basal Sham 197 ± 6.653 
RAPC 98.5 ± 4.976* 
L-NAME pretreatment in Sham 180.833 ± 3.419 
L-NAME pretreatment in RAPC 179.5 ± 0.582* 
Immediate Reperfusion Sham 1310.167 ± 22.511* 
RAPC 336 ± 10.906* 
L-NAME pretreatment in Sham 807.833 ± 10.406 
L-NAME pretreatment in RAPC 808.031 ± 4.379* 
30 minute Reperfusion Sham 999 ± 34.438 
RAPC 207.833 ± 10.134* 
L-NAME pretreatment in Sham 902.833 ± 10.613 
L-NAME pretreatment in RAPC 896.243 ± 7.892* 
 Aminoguanidine (150 mg/Kg s.c.) pretreatment (FWOP) Basal Sham 197 ± 6.653 
RAPC 98.5 ± 4.976* 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in Sham 180.833 ± 3.419 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in RAPC 83.3 ± 0.601* 
Immediate Reperfusion Sham 1310.167 ± 22.511* 
RAPC 336 ± 10.906* 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in Sham 807.833 ± 10.406 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in RAPC 347.333 ± 5.690* 
30 minute Reperfusion Sham 999 ± 34.438 
RAPC 207.833 ± 10.134* 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in Sham 902.833 ± 10.613 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in RAPC 231.333 ± 6.448* 
Aminoguanidine (300 mg/Kg s.c.) pretreatment (FWOP) Basal Sham 216.947 ± 2.756 
RAPC 106.621 ± 8.796* 
Aminoguanidine(300 mg/Kg s.c.) pretreatment in Sham 188.639 ± 12.137 
Aminoguanidine(300 mg/Kg s.c.) pretreatment in RAPC 198.723 ± 7.105 
Immediate Reperfusion Sham 1402.172 ± 25.347* 
RAPC 342.926 ± 14.488* 
Aminoguanidine (300 mg/Kg s.c.)  pretreatment in Sham 827.833 ± 17.786 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in RAPC 346.342 ± 6.780* 
30 minute Reperfusion Sham 1062.415 ± 24.368* 
RAPC 219.623 ± 15.462* 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in Sham 1102.833 ± 15.134 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in RAPC 230.372 ± 7.822* 
S-methyl isothiourea (3 mg/Kg i.v) pretreatment FWOP) Basal Sham 239.452 ± 17.531 
RAPC 111.133 ± 12.673* 
S-methyl isothiourea pretreatment in Sham 179.937 ± 14.762 
S-methyl isothiourea pretreatment in RAPC 211.385 ± 14.178 
Immediate Reperfusion Sham 1382.194 ± 23.848* 
RAPC 337.963 ± 19.863* 
S-methyl isothiourea pretreatment in Sham 836.623 ± 27.637 
S-methyl isothiourea pretreatment in RAPC 352.262 ± 13.840* 
30 minute Reperfusion Sham 1069.415 ± 24.368* 
RAPC 223.377 ± 18.682* 
S-methyl isothiourea pretreatment in Sham 1104.373 ± 24.345 
S-methyl isothiourea pretreatment in RAPC 226.252 ± 17.223* 
1400W (1 mg/Kg i.v)  pretreatment (FWOP) Basal Sham 239.452 ± 17.531 
RAPC 111.133 ± 12.673* 
1400W pretreatment in Sham 185.357 ± 10.652 
1400W pretreatment in RAPC 223.539 ± 18.768 
Immediate Reperfusion Sham 1382.194 ± 23.848* 
RAPC 337.963 ± 19.863* 
1400W pretreatment in Sham 836.623 ± 27.637 
1400W pretreatment in RAPC 352.262 ± 13.840* 
30 minute Reperfusion Sham 1069.415 ± 24.368* 
RAPC 223.377 ± 18.682* 
1400W pretreatment in Sham 1131.468 ± 4.485 
1400W pretreatment in RAPC 231.723 ± 22.846* 
LDH was estimated af ter  s tabi l isat ion (Basal),  immediately (Imm) and 30 min (30 ')  af ter  reperfusion,  sham denoted that  rats  were not  subjected to  remote 
precondit ioning by aort ic constriction and RPAC denoted that  rats  were subjected to  remote precondi tioning by aort ic constriction.   Values are mean ± S.E.M. of  s ix 
experiments .  *= p<0.05 vs  Sham as  compared to  i ts  respective basal  value. 
 
 
Table - 4: Acute Effect (SWOP) of  Remote Preconditioning  by Aortic Constriction  and NOS inhibitors  Pretreatment on Lactate Dehydrogenase (LDH) Release in coronary Effluent of  
Isolated Rat Heart Subjected to Global Ischaemia (30 min) followed by Reperfusion (120 min). 
L-NAME (10 mg/Kg i.v) pretreatment (SWOP) Basal Sham 207.294 ± 0.420 
RAPC 83.667 ± 0.529* 
L-NAME pretreatment in Sham 196 ± 1.358 
L-NAME pretreatment in RAPC 198.667 ± 0.831 
Immediate Reperfusion Sham 902.583 ± 15.290* 
RAPC 131.806 ± 5.333* 
L-NAME pretreatment in Sham 821.463 ± 13.472 
L-NAME pretreatment in RAPC 792.762 ± 7.036 
30 minute Reperfusion Sham 204.343 ± 5.533* 
RAPC 92.427 ± 1.587* 
L-NAME pretreatment in Sham 187.385 ± 6.333 
L-NAME pretreatment in RAPC 190.563 ± 3.416 
 Aminoguanidine (150 mg/Kg s.c.) pretreatment (SWOP) Basal Sham 199.667 ± 0.760 
RAPC 89.667 ± 0.667* 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in Sham 193 ± 1.065 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in RAPC 183.667 ± 0.333 
Immediate Reperfusion Sham 852.5 ± 12.529* 
RAPC 101.333 ± 5.806* 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in Sham 803.333 ± 11.427 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in RAPC 783.667 ± 5.596 
30 minute Reperfusion Sham 198.333 ± 8.815* 
RAPC 80.333 ± 1.358* 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in Sham 177.5 ± 4.233 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in RAPC 182.5 ± 2.141 
Aminoguanidine (300 mg/Kg s.c.) pretreatment (SWOP) Basal Sham 207.294 ± 0.420 
RAPC 83.667 ± 0.529* 
Aminoguanidine(300 mg/Kg s.c.) pretreatment in Sham 196 ± 1.358 
Aminoguanidine(300 mg/Kg s.c.) pretreatment in RAPC 198.667 ± 0.831 
Immediate Reperfusion Sham 902.583 ± 15.290* 
RAPC 131.806 ± 5.333* 
Aminoguanidine (300 mg/Kg s.c.)  pretreatment in Sham 821.463 ± 13.472 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in RAPC 792.762 ± 7.036 
30 minute Reperfusion Sham 204.343 ± 5.533* 
RAPC 92.427 ± 1.587* 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in Sham 187.385 ± 6.333 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in RAPC 190.563 ± 3.416 
S-methyl isothiourea (3 mg/Kg i.v) pretreatment (SWOP) Basal Sham 214.954 ± 14.230 
RAPC 102.340 ± 12.425* 
S-methyl isothiourea pretreatment in Sham 176 ± 11.538 
S-methyl isothiourea pretreatment in RAPC 189.727 ± 10.127 
Immediate Reperfusion Sham 1002.583 ± 14.231* 
RAPC 124.318 ± 4.395* 
S-methyl isothiourea pretreatment in Sham 848.634 ± 11.437 
S-methyl isothiourea pretreatment in RAPC 824.527 ± 17.327 
30 minute Reperfusion Sham 192.463 ± 13.334* 
RAPC 98.241 ± 13.552* 
S-methyl isothiourea pretreatment in Sham 192.331 ± 6.459 
S-methyl isothiourea pretreatment in RPAC 188.693 ± 12.156 
1400W (1 mg/Kg i.v)  pretreatment (SWOP) Basal Sham 207.294 ± 0.420 
RPAC 83.667 ± 0.529* 
1400W pretreatment in Sham 204.593 ± 1.871 
1400W pretreatment in RPAC 213.429 ± 0.361 
Immediate Reperfusion Sham 902.583 ± 15.290* 
RPAC 131.806 ± 5.333* 
1400W pretreatment in Sham 816.361 ± 14.792 
1400W pretreatment in RPAC 832.642 ± 16.386 
30 minute Reperfusion Sham 204.343 ± 5.533* 
RPAC 92.427 ± 1.587* 
1400W pretreatment in Sham 203.865 ± 19.592 
1400W pretreatment in RPAC 225.724 ± 12.426 
 
LDH was estimated af ter  s tabi l isat ion (Basal),  immediately (Imm) and 30 min (30 ')  af ter  reperfusion,  sham denoted that  rats  were not  subjected to  remote 
precondit ioning by aort ic constriction and RPAC denoted that  rats  were subjected to  remote precondi tioning by aort ic constriction.   Values are mean ± S.E.M. of  s ix 
experiments .  *= p<0.05 vs  Sham as  compared to  i ts  respective basal  value. 
 
 
 
Table 5:  Acute Effect (FWOP) of Remote Preconditioning  by Aortic Constriction and NOS inhibitors Pretreatment on Creatine Kinase (CK) Release in coronary Effluent of Isolated Rat 
Heart Subjected to Global Ischaemia (30 min) followed by Reperfusion (120 min). 
L-NAME (10 mg/Kg i.v) pretreatment (FWOP) Basal Sham 20.167 ± 0.601 
RPAC 2.167 ± 1.078*  
L-NAME pretreatment in Sham 22.333 ± 1.116  
L-NAME pretreatment in RPAC 23.927 ± 0.475  
5 minute Reperfusion Sham 140.5 ± 4.015* 
RPAC 30.5 ± 2.172* 
L-NAME pretreatment in Sham 126.5 ± 3.731 
L-NAME pretreatment in RPAC 133.5 ± 2.232 
 Aminoguanidine (150 mg/Kg s.c.) pretreatment (FWOP) Basal Sham 20.167 ± 0.601 
RPAC 2.167 ± 1.078*  
Aminoguanidine(150 mg/Kg s.c.) pretreatment in Sham 22.333 ± 1.116  
Aminoguanidine(150 mg/Kg s.c.) pretreatment in RPAC 07 ± 0.683*  
5 minute Reperfusion Sham 140.5 ± 4.015* 
RPAC 30.5 ± 2.172* 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in Sham 126.5 ± 3.731 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in RPAC 43.5 ± 2.232 
Aminoguanidine (300 mg/Kg s.c.) pretreatment (FWOP) Basal Sham 20.167 ± 0.601 
RPAC 2.167 ± 1.078*  
Aminoguanidine(300 mg/Kg s.c.) pretreatment in Sham 22.333 ± 1.116  
Aminoguanidine(300 mg/Kg s.c.) pretreatment in RPAC 07 ± 0.683*  
5 minute Reperfusion Sham 140.5 ± 4.015* 
RPAC 30.5 ± 2.172* 
Aminoguanidine (300 mg/Kg s.c.)  pretreatment in Sham 126.5 ± 3.731 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in RPAC 59.5 ± 2.232* 
S-methyl isothiourea (3 mg/Kg i.v) pretreatment (FWOP) Basal Sham 22.627 ± 0.652 
RPAC 3.263 ± 1.738*  
S-methyl isothiourea pretreatment in Sham 24.333 ± 1.346  
S-methyl isothiourea pretreatment in RPAC 08.934 ± 0.832*  
5 minute Reperfusion Sham 152.563 ± 3.515* 
RPAC 33.725 ± 4.259* 
S-methyl isothiourea pretreatment in Sham 134.5 ± 4.318 
S-methyl isothiourea pretreatment in RPAC 36.5 ± 3.542 
1400W (1 mg/Kg i.v)  pretreatment (FWOP) Basal Sham 20.167 ± 0.601 
RPAC 2.167 ± 1.078*  
1400W pretreatment in Sham 22.333 ± 1.116  
1400W pretreatment in RPAC 07 ± 0.683*  
5 minute Reperfusion Sham 140.529 ± 4.015* 
RPAC 63.084 ± 2.172* 
1400W pretreatment in Sham 126.821 ± 3.731 
1400W pretreatment in RPAC 67.284 ± 2.232 
LDH was estimated af ter  s tabi l isat ion (Basal),  immediately (Imm) and 30 min (30 ')  af ter  reperfusion,  sham denoted that  rats  were not  subjected to  remote 
precondit ioning by aort ic constriction and RPAC denoted that  rats  were subjected to  remote precondi tioning by aort ic constriction.   Values are mean ± S.E.M. of  s ix 
experiments .  *= p<0.05 vs  Sham as  compared to  i ts  respective basal  value. 
  
 
 
 
Table 6:  Delayed Effect (SWOP)  of Remote Preconditioning  by Aortic Constriction and NOS inhibitors Pretreatment on Creatine Kinase (CK) Release in coronary Effluent of Isolated 
Rat Heart Subjected to Global Ischaemia (30 min) followed by Reperfusion (120 min). 
L-NAME (10 mg/Kg i.v) pretreatment (FWOP) Basal Sham 40.167 ± 2.937 
RPAC 18.333 ± 2.565* 
L-NAME pretreatment in Sham 38.167 ± 2.428 
L-NAME pretreatment in RPAC 23.421 ± 1.751* 
5 minute Reperfusion Sham 233.5 ± 19.155* 
RPAC 43.5 ± 2.012* 
L-NAME pretreatment in Sham 203 ± 9.856 
L-NAME pretreatment in RPAC 121.647 ± 12.246* 
 Aminoguanidine (150 mg/Kg s.c.) pretreatment (FWOP) Basal Sham 40.167 ± 2.937 
RPAC 18.333 ± 2.565* 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in Sham 38.167 ± 2.428 
Aminoguanidine(150 mg/Kg s.c.) pretreatment in RPAC 36 ± 1.751 
5 minute Reperfusion Sham 233.5 ± 19.155* 
RPAC 43.5 ± 2.012* 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in Sham 203 ± 9.856 
Aminoguanidine (150 mg/Kg s.c.)pretreatment in RPAC 237.167 ± 3.842 
Aminoguanidine (300 mg/Kg s.c.) pretreatment (FWOP) Basal Sham 40.167 ± 2.937 
RPAC 18.333 ± 2.565* 
Aminoguanidine(300 mg/Kg s.c.) pretreatment in Sham 38.167 ± 2.428 
Aminoguanidine(300 mg/Kg s.c.) pretreatment in RPAC 36 ± 1.751 
5 minute Reperfusion Sham 233.5 ± 19.155* 
RPAC 43.5 ± 2.012* 
Aminoguanidine (300 mg/Kg s.c.)  pretreatment in Sham 203 ± 9.856 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in RPAC 237.167 ± 3.842 
S-methyl isothiourea (3 mg/Kg i.v) pretreatment (FWOP) Basal Sham 43.617 ± 3.657 
RPAC 17.426 ± 4.585* 
S-methyl isothiourea pretreatment in Sham 40.524 ± 3.258 
S-methyl isothiourea pretreatment in RPAC 39.469 ± 2.541 
5 minute Reperfusion Sham 236.5 ± 9.553* 
RPAC 45.483 ± 3.126* 
S-methyl isothiourea pretreatment in Sham 205.930 ± 10.567 
S-methyl isothiourea pretreatment in RPAC 229.167 ± 5.835 
1400W (1 mg/Kg i.v)  pretreatment (FWOP) Basal Sham 40.167 ± 2.937 
RPAC 18.333 ± 2.565* 
1400W pretreatment in Sham 37.616 ± 2.428 
1400W pretreatment in RPAC 36.83 ± 1.751 
5 minute Reperfusion Sham 233.5 ± 19.155* 
RPAC 43.5 ± 2.012* 
1400W pretreatment in Sham 213 ± 9.856 
1400W pretreatment in RPAC 226.167 ± 2.242 
LDH was estimated af ter  s tabi l isat ion (Basal),  immediately (Imm) and 30 min (30 ')  af ter  reperfusion,  sham denoted that  rats  were not  subjected to  remote 
precondit ioning by aort ic constriction and RPAC denoted that  rats  were subjected to  remote precondi tioning by aort ic constriction.   Values are mean ± S.E.M. of  s ix 
experiments .  *= p<0.05 vs  Sham as  compared to  i ts  respective basal  value. 
 
 
Table-7: Acute Effect of Remote Preconditioning  by Aortic Constriction and NOS inhibitors Pretreatment on Myocardial Infarct Size in Isolated Rat Heart Subjected to Global Ischaemia 
(30 min) followed by Reperfusion (120 min):  
L-NAME (10 mg/Kg i.v) 
pretreatment (FWOP) 
% Infract By Volume Sham 41.167 ± 1.662 
RPAC 24.934 ± 1.238* 
Aminoguanidine pretreatment in Sham 45.5 ± 1.979 
Aminoguanidine pretreatment in RPAC 46.167 ± 0.872 
% Infract By Weight Sham 42.5 ± 2.592 
RPAC 27.833 ± 1.662* 
Aminoguanidine pretreatment in Sham 47 ± 1.414 
Aminoguanidine pretreatment in RPAC 46.667 ± 1.308 
Aminoguanidine (150 mg/Kg 
s.c.) pretreatment (FWOP) 
% Infract By Volume Sham 41.167 ± 1.662 
RPAC 24 ± 1.238* 
Aminoguanidine pretreatment in Sham 45.5 ± 1.979 
Aminoguanidine pretreatment in RPAC 30.167 ± 0.872* 
% Infract By Weight Sham 42.5 ± 2.592 
RPAC 27.833 ± 1.662* 
Aminoguanidine pretreatment in Sham 47 ± 1.414 
Aminoguanidine pretreatment in RPAC 27.667 ± 1.308* 
Aminoguanidine (300 mg/Kg 
s.c.) pretreatment (FWOP) 
% Infract By Volume Sham 42.274 ± 3.732 
RPAC 23.429 ± 2.368* 
Aminoguanidine pretreatment in Sham 46.425 ± 2.079 
Aminoguanidine pretreatment in RPAC 30.290 ± 0.977* 
% Infract By Weight Sham 42.578 ± 2.392 
RPAC 28.333 ± 1.766* 
Aminoguanidine pretreatment in Sham 47.472 ± 1.741 
Aminoguanidine pretreatment in RPAC 26.733 ± 2.468* 
S-methyl isothiourea (3 mg/Kg % Infract By Volume Sham 40.333 ± 4.724 
i.v) pretreatment (FWOP) RPAC 24.728 ± 2.383* 
Aminoguanidine pretreatment in Sham 45.541 ± 2.799 
Aminoguanidine pretreatment in RAPC 31.673 ± 1.726* 
% Infract By Weight Sham 42.500 ± 3.924 
RAPC 26.833 ± 2.674* 
Aminoguanidine pretreatment in Sham 47.000 ± 2.414 
Aminoguanidine pretreatment in RPAC 26.667 ± 2.338* 
1400W (1 mg/Kg i.v)  
pretreatment (FWOP) 
% Infract By Volume Sham 43.67 ± 1.662 
RAPC 24.859 ± 1.238* 
Aminoguanidine pretreatment in Sham 45.5 ± 1.979  
Aminoguanidine pretreatment in RPAC 44.167 ± 0.872 
% Infract By Weight Sham 42.5 ± 2.592 
RPAC 27.833 ± 1.662* 
Aminoguanidine pretreatment in Sham 47 ± 1.414 
Aminoguanidine pretreatment in RPAC 48.667 ± 1.308 
 
Sham denoted that  rats  were not  subjected to  remote remote precondit ioning by aort ic constriction and RPAC denoted that  rats  were subjected to  remote  
precondit ioning by aort ic constriction.  Values are  mean ± S.E.M. of  six experiments .  *  = p<0.05 vs  Sham 
 
 
Table-8: Delayed Effect of Remote Preconditioning  by Aortic Constriction and NOS inhibitors Pretreatment on Myocardial Infarct Size in Isolated Rat Heart Subjected to Global Ischaemia 
(30 min) followed by Reperfusion (120 min):  
L-NAME (10 mg/Kg i.v) 
pretreatment (SWOP) 
% Infract By Volume Sham 45.167 ± 1.424 
RPAC 24.5 ± 0.764* 
L-NAME pretreatment in Sham 45 ± 1.238 a 
L-NAME pretreatment in RPAC 45.333 ± 1.430 a 
% Infract By Weight Sham 45 ± 0.966 
RPAC 24.167 ± 0.872* 
L-NAME pretreatment in Sham 45.333 ± 1.116 a 
L-NAME pretreatment in RPAC 47 ± 1.461 
Aminoguanidine (150 mg/Kg 
s.c.) pretreatment (SWOP) 
% Infract By Volume Sham 45.167 ± 1.424 
RPAC 24.5 ± 0.764 a 
Aminoguanidine (150 mg/Kg s.c.)  pretreatment in Sham 45 ± 1.238 
Aminoguanidine (150 mg/Kg s.c.)  pretreatment in RPAC 45.333 ± 1.430 
% Infract By Weight Sham 45 ± 0.966 
RPAC 24.167 ± 0.872* 
Aminoguanidine (150 mg/Kg s.c.) pretreatment in Sham 45.333 ± 1.116 
Aminoguanidine (150 mg/Kg s.c.)  pretreatment in RPAC 47 ± 1.461  
Aminoguanidine (300 mg/Kg 
s.c.) pretreatment (SWOP) 
% Infract By Volume Sham 44.675 ± 2.434 
RPAC 24.568 ± 1.767* 
Aminoguanidine (300 mg/Kg s.c.)  pretreatment in Sham 45.783 ± 1.253 
Aminoguanidine (300 mg/Kg s.c.)  pretreatment in RPAC 46.232 ± 1.630 
% Infract By Weight Sham 45.024 ± 1.667 
RPAC 24.667 ± 0.762* 
Aminoguanidine (300 mg/Kg s.c.)  pretreatment in Sham 45.933 ± 3.121 
Aminoguanidine (300 mg/Kg s.c.) pretreatment in RPAC 47.672 ± 2.346  
S-methyl isothiourea (3 mg/Kg 
i.v) pretreatment (SWOP) 
% Infract By Volume Sham 48.528 ± 2.246 
RPAC 24.558 ± 1.674*  
S-methyl isothiourea pretreatment in Sham 45.000 ± 2.283 
S-methyl isothiourea pretreatment in RPAC 45.533 ± 4.436 
% Infract By Weight Sham 45.824 ± 0.966 
RPAC 23.783 ± 0.724* 
S-methyl isothiourea pretreatment in Sham 45.333 ± 1.116 
S-methyl isothiourea pretreatment in RPAC 47.000 ± 4.244 
1400W (1 mg/Kg i.v)  
pretreatment (SWOP) 
% Infract By Volume Sham 45.167 ± 1.424 
RPAC 24.5 ± 0.764* 
1400W pretreatment in Sham 45 ± 1.238 
1400W pretreatment in RPAC 45.333 ± 1.430 
% Infract By Weight Sham 45 ± 0.966 
RPAC 24.167 ± 0.872* 
1400W pretreatment in Sham 45.333 ± 1.116 
1400W pretreatment in RPAC 47 ± 1.461  
 
Sham denoted that  rats  were not  subjected to remote precondit ioning by aort ic constriction and RPAC denoted that  rats  were subjected to remote precondit ioning by 
aort ic constriction.  Values are mean ± S.E.M. of  s ix  experiments .  *  = p<0.05 vs Sham 
 
 
 
 
